^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hodgkin Lymphoma

    Related cancers:
    1d
    CD45BE-HSPC + CART-45 Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, University of Pennsylvania
    New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    1d
    BV-ALLO: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=14, Completed, University of Cologne | Recruiting --> Completed | N=21 --> 14
    Trial completion • Enrollment change
    |
    Adcetris (brentuximab vedotin)
    2d
    EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Daihong Liu
    New P1/2 trial
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    2d
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, St. Jude Children's Research Hospital | N=140 --> 69 | Trial completion date: Aug 2025 --> Jun 2026
    Enrollment change • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    2d
    CALySSEY: CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors (clinicaltrials.gov)
    P1, N=88, Not yet recruiting, Baylor College of Medicine | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    2d
    BEGEV: Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=88, Completed, Cairo University
    New P3 trial
    |
    cisplatin • gemcitabine • vinorelbine tartrate • dexamethasone • bendamustine
    2d
    INDIE: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, University of Cologne | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tevimbra (tislelizumab-jsgr)
    2d
    Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma (clinicaltrials.gov)
    P=N/A, N=475, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    tamoxifen
    3d
    SPELH: Sperm Epigenome in Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Rennes University Hospital
    New trial
    4d
    GFAOPLH2019: Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, French Africa Pediatric Oncology Group | Trial completion date: Nov 2034 --> Dec 2030 | Trial primary completion date: Aug 2029 --> Dec 2028
    Trial completion date • Trial primary completion date
    5d
    An Unusual Case of Anti-FGFR3 Antibodies, Sensory Neuropathy, and Adie Pupil in a Patient With Hodgkin Lymphoma in Remission and Review of the Literature. (PubMed, J Clin Neuromuscul Dis)
    In addition to the case report, we provide a review of the literature on anti-FGFR3-positive sensory neuropathy. To our knowledge, this is the first report of Adie pupil in a patient with anti-FGFR3 antibodies.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3)